- Low doses of LSD significantly increase BDNF levels in healthy volunteers, with effects peak at 4 and 6 hours post-administration.
- The study revealed that BDNF levels were affected variably by different LSD doses, indicating a complex relationship that requires further exploration.
- Increased BDNF levels resulting from low-dose LSD may be linked to potential therapeutic effects in psychiatric conditions through enhanced neuroplasticity.
Introduction to the Study
This publication is the second of a comprehensive four-part investigation into the effects of low doses of LSD on neuronal functioning. The researchers focused specifically on the impact of microdosing LSD (20µg) on neuroplasticity, which they measured through the levels of brain-derived neurotrophic factor (BDNF). While they found that BDNF levels increased at six hours post-administration, the findings were not consistent across all measurements and time points, suggesting variability in the effects of LSD on neuroplasticity.
Methodology and Key Observations
The study included healthy volunteers who were administered various low doses of LSD (5, 10, and 20 µg) to measure circulating BDNF levels, with blood samples taken over a span of six hours after dosing. The results indicated a notable increase in BDNF levels two hours and four hours after the LSD was ingested, specifically highlighting the doses of 5 µg at four hours and both 5 µg and 20 µg at six hours when compared to a placebo group.
Various psychedelics, including LSD, have been shown in previous research to promote neuroplasticity, a mechanism that underlies learning and memory. Prior work indicated that sustenance of high BDNF levels correlated with chronic administration of psychedelics, thereby positing a link between such substances and therapeutic potential for mental health disorders, particularly those linked to neuroplasticity vulnerabilities, like depression.
Discussion of Findings
It was also noted that difficulties with blood sample collection created gaps in data, which necessitated statistical analysis only on complete data sets. Despite this complication, analysis revealed that an increasing dose of LSD corresponded with changes in BDNF levels, with 5 µg showing the most significant initial response. These results suggest that the response to 20 µg of LSD may require a longer observation period to fully understand its effect on BDNF levels.
Specifically, BDNF levels appeared to peak earlier for the lowest dose, while higher doses continued to show increased levels beyond the immediate post-administration window. These findings suggest that appropriately timed assessments could yield deeper insights, emphasizing the need for further research on dosing and its timing in relation to BDNF responses.
Conclusion and Future Directions
In conclusion, the study establishes a correlation between low doses of LSD and increased BDNF levels within healthy volunteers, indicating possible implications for therapeutic and cognitive enhancement benefits. It highlights not only the importance of understanding these effects but also suggests that future studies could explore the long-term benefits of psychedelics on neuroplasticity, particularly in populations with psychiatric concerns. The research inadvertently sets the stage for a nuanced exploration of how various psychedelics might work collectively or individually to influence neuroplastic mechanisms in the human brain.
Read the full paper summary on Blossom.
